目的观察阿德福韦酯治疗对α-干扰素无应答的CHB患者的疗效。方法27例对α-干扰素无应答的CHB患者,口服阿德福韦酯10mg,1次/日,随访至18个月,观察肝功能、乙型肝炎病毒标记物及HBV DNA的变化情况。结果27例患者在6个月、12个月和18个月时HBV DNA阴转率分别为18.5%、29.6%和44.4%;ALT复常率分别为88.9%、92.6%和85.2%;HBeAg血清学转换率分别为7.4%、14.8%和25.9%。结论阿德福韦酯治疗对α-干扰素无应答的CHB患者的疗效随疗程的延长逐渐增加。 Objective To observe the efficacy of adefovir dipivoxil in patients with CHB who did not respond to IFN-α. Methods Twenty-seven patients with CHB who did not respond to interferon-alpha were given oral adefovir dipivoxil 10 mg once daily for 18 months. The changes of liver function, HBV markers and HBV DNA were observed. Results The 27 cases had 18.5%, 29.6% and 44.4% of HBV DNA negative conversion rates at 6 months, 12 months and 18 months respectively. The rates of abnormal ALT were 88.9%, 92.6% and 85.2%, respectively. HBeAg serum School conversion rates were 7.4%, 14.8% and 25.9% respectively. Conclusion The efficacy of adefovir dipivoxil treatment in patients with CHB who did not respond to interferon-alpha increased gradually with the course of treatment.